To evaluate whether orelabrutinib combined with romiplostim N01 can improve the quality of remission, increase the probability of successful drug withdrawal, and prolong the time to treatment failure in patients with primary immune thrombocytopenia (ITP) who have received at least one line of prior therapy.
Subjects voluntarily participate in this study and provide written informed consent；
Age 18-80 years, inclusive, regardless of gender；
ECOG score 0 to 2；
Documented diagnosis of chronic primary Immune Thrombocytopenia (ITP) with a disease duration >12 months；
Subjects suffer from severe ITP at screening;
Subjects have other diseases which mention in protocol;
Subjects develop intracranial hemorrhage within 6 months prior to screening;
Active and uncontrollable infection;